Celltrion Pharm셀트리온제약
068760 · KOSDAQ · ₩068760 · 셀트리온제약
₩36,800▼ ₩300 (0.81%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 31.1% | 30.5% | 25.5% | 30.8% | 29.2% | 29.9% |
| Operating margin | 10.7% | 10.5% | 7.8% | 9.3% | 9.9% | 12.0% |
| Net margin | 7.2% | 7.2% | 4.6% | 5.5% | 6.7% | 8.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +7.8% | +12.3% | +22.9% | +0.7% | −3.2% | — |
| Operating income growth | +10.6% | +50.7% | +3.2% | −5.5% | −20.1% | — |
| Net income growth | +6.8% | +76.4% | +3.3% | −18.1% | −24.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 9.4% | 9.3% | 5.7% | 5.8% | 7.5% | 10.4% |
| Return on assets | 5.4% | 5.4% | 3.4% | 3.4% | 4.2% | 5.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 73.5% | 74.2% | 68.7% | 70.3% | 68.1% | 92.2% |
| Net debt to equity | 20.1% | 21.1% | 27.6% | 36.8% | 36.1% | 30.1% |
| Current ratio | 171.4% | 165.9% | 158.2% | 146.3% | 147.1% | 127.4% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Celltrion Pharm / 셀트리온제약 / 068760 / KRX:068760
Source: KRX statistical information